First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study

BACKGROUND: Endocrine therapy (ET) plus cyclin-dependent-kinases 4/6 inhibitors (CDK4/6i) represents the standard treatment for luminal-metastatic breast cancer (MBC). However, prospective head-to-head comparisons are still lacking for 1st line (L) options, and it is still crucial to define the best...

Descripción completa

Detalles Bibliográficos
Autores principales: Basile, Debora, Gerratana, Lorenzo, Corvaja, Carla, Pelizzari, Giacomo, Franceschin, Giorgia, Bertoli, Elisa, Palmero, Lorenza, Zara, Diego, Alberti, Martina, Buriolla, Silvia, Da Ros, Lucia, Bonotto, Marta, Mansutti, Mauro, Spazzapan, Simon, Cinausero, Marika, Minisini, Alessandro Marco, Fasola, Gianpiero, Puglisi, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053791/
https://www.ncbi.nlm.nih.gov/pubmed/33812267
http://dx.doi.org/10.1016/j.breast.2021.02.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053791/
https://www.ncbi.nlm.nih.gov/pubmed/33812267
http://dx.doi.org/10.1016/j.breast.2021.02.015

Ejemplares similares